Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check4 days agoChange DetectedThe website footer revision changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check11 days agoChange DetectedThe clinical trial record for daratumumab and donor lymphocyte infusion in relapsed acute myeloid leukemia is displayed with its study details, participation criteria, outcomes, record dates, and supporting documents. The record indicates the study was terminated due to poor accrual and is no longer recruiting participants.SummaryDifference58%

- Check18 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study page continues to show a 403 Forbidden response.SummaryDifference0.2%

- Check32 days agoChange DetectedA notice about NIH website terminology changes appears above the 403 error page, and the site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe ClinicalTrials.gov error page’s footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating an access issue that hides the study details. This blocks viewing the core information for the NCT03537599 entry on ClinicalTrials.gov.SummaryDifference20%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.